A study found that baseline platelet count, ASXL1 mutation, and Revised International Prognostic Scoring System (IPSS-R) status were the most important predictors of response to imetelstat in…

Geron (Nasdaq: GERN) reported second quarter 2026 RYTELO® (imetelstat) net product revenue of $57.5 million, up 11% versus Q1 2026 and above $49.0 million a year ago. Total Q2 revenues were $57.5 million, with a net loss of $16.7 million, or $0.02 per share.Total Q2 costs and operating expenses were $70.0 million, up from $61.5 million, driven primarily by non-cash inventory-related expenses, as cost of goods sold rose to $9.2 million. Geron ended Q2 2026 with $326.9 million in cash, cash equivalents, restricted cash and marketable securities.For full-year 2026, Geron reiterated guidance for RYTELO net product revenue of $220–$240 million and total operating expenses of $230–$240 million. The company highlighted continued RYTELO demand growth, expansion of ordering accounts, real-world and clinical data presentations, and the appointment of a new Chief Business Officer.

Geron (Nasdaq: GERN) announced the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), to be presented at EHA 2026. The Moffitt Cancer Center study in 40 heavily pretreated, transfusion-dependent patients showed 37.5% achieving ≥8-week RBC transfusion independence and a safety profile consistent with prior data.Geron will also present updated myelofibrosis overall survival analyses and early-phase acute myeloid leukemia and myelofibrosis combination trial data at EHA 2026 and ASCO 2026.

Achieved $51.8 million in RYTELO ® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240

Blood Cancer Journal - Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Geron (NASDAQ:GERN) executives used a presentation at the Needham Healthcare Conference to outline the company’s early commercial trajectory for its telomerase inhibitor imetelstat (marketed as RYTELO) in lower-risk myelodysplastic syndromes (MDS), provide updated views on physician adoption dynamic

Imetelstat was associated with sustained improvements in fatigue and QOL alongside RBC transfusion independence in MDS.

Amer Zeidan: And Then Came the 1st Successful Targeting in Human Disease with Imetelstat... / Amer Zeidan, cancer, OncoDaily, Oncology, The Nobel Prize

Targeting telomerase in myelodysplastic syndrome: imetelstat as a disease-modifying therapy for transfusion-dependent patients

Geron (Nasdaq: GERN) announced five presentations accepted for ASH 2025 (Dec 6-9, Orlando) reporting new clinical and translational analyses of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS) and myelofibrosis (MF).Highlights include an oral IMerge Phase 3 analysis linking treatment-emergent cytopenias to clinical response in LR-MDS (Dec 7), a long-term IMerge poster with a ≥42-month overall survival trend versus placebo (Dec 6), MF biomarker and cytokine-response analyses from IMbark, an IMproveMF combination trial update, and an investigator-led interim IMpress study in high-risk MDS/AML.

John Mascarenhas, MD, discusses early findings from the IMproveMF trial combining imetelstat with ruxolitinib in intermediate- to high-risk myelofibrosis.